Paper Review Records
全部论文审稿周期
20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
110
天
CircRNA-mediated regulation of ferroptosis in cancer: mechanistic networks and therapeutic implications
作者
Yuliang Zhang; Xingyu Du; Jin Liu; Yujia Guo; Xiaoxia Wang展开收起
作者单位
1. Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, China; 2. Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, China展开收起
305
天
METTL3-mediated m⁶A methylation of E2F2 targets MCU to promote the malignant phenotype of gastric cancer cells
作者
Huan Liu; ZhongCong Guo; Lan Li; YuXuan Dong; Nian Chen; ZhengTai Yuan展开收起
作者单位
1. Department of Gastrointestinal Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha City, China; 2. Oncology Medical Center, The First Hospital of Hunan University of Chinese Medicine, Changsha City, China展开收起
166
天
Targeted degradation of protein in hematologic malignancies: mechanisms, therapeutic strategies, and clinical prospects
作者
Sana Nafees; Glowi Alasiri; Mohammad Suhail Akhter; Nemat Ali展开收起
作者单位
1. Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia; 2. Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia; 3. MLT department, College of Nursing and Health Sciences, Jazan University, Jizan, Saudi Arabia; 4. Health Research Center, Jazan University, Jizan, Saudi Arabia; 5. Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia展开收起
326
天
TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming
作者
Mengwei Zhang; Yu Wang; Siyi Li; Gengwei Huo; Yuchao He; Xiaomeng Hu; Wenshuai Chen; Xinrui Wen; Liwei Chen; Yi Luo; Peng Chen; Hua Guo展开收起
作者单位
1. Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 2. National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; 3. Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; 4. Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 5. Department of Ultrasound Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China展开收起
193
天
CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8 + T cells
作者
Chunli Zhang; Qiuxia Wei; Nigmat Rahim; Gang Bian; Chaoling Wu; Jing Wang; Ping Yang; Jiahui Hua; Mingxia Zhu; Yingtong Chen; Yan Liu; Shuang Gao; Bing Hou; Weilong Zhang; Hongmei Jing展开收起
作者单位
1. Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China; 2. Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; 3. Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing, China; 4. Shanghai Antengene Corporation Limited, Shanghai, China; 5. Department of Respiratory medicine, Affiliated Hospital of Jiujiang University, Jiujiang, China展开收起
287
天
Targeting HDAC and proteostasis to eradicate quiescent cancer cells
作者
Qi Jiang; Michelle Ertel; Austin Arrigo; Amjad Hijazzi; Sara Sannino; Jennifer L. Goeckeler-Fried; April Sagan; Ian Beddows; Betsy Ann Varghese; Daniel D. Brown; Wayne Stallaert; Adrian Lee; Amanda M. Clark; Hui Shen; Jeffrey L. Brodsky; Hatice U. Osmanbeyoglu; Ronald J. Buckanovich展开收起
作者单位
1. Obstetrics and Gynecology Magee-Womens Research Inst. & Foundation, Pittsburgh, USA; 2. School of Medicine, Tsinghua University, Beijing, China; 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, USA; 4. Department of Biological Sciences, University of Pittsburgh, Pittsburgh, USA; 5. Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, USA; 6. Van Andel Institute, Grand Rapids, USA; 7. Department of Computational and Systems Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; 8. Department of Pharmacology, University of Pittsburgh, Pittsburgh, USA; 9. Department of Pathology, University of Pittsburgh, Pittsburgh, USA; 10. Department of Internal Medicine, UPMC Hillman Cancer Center, Pittsburgh, USA展开收起
FAQ
CANCER GENE THERAPY审稿要多久?
截至2026-11-19,CrushSCI 收录了 CANCER GENE THERAPY 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 102 天(The paradox of miR-107 in oncology: dual roles as a tumor suppressor and oncomiR,2026-02-02 收稿,2026-05-15 录用),最慢一篇用了 408 天;平均 233 天,中位数 225.5 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
